Carboplatin (NSC 241240)

Catalog No.S1215 Synonyms: JM-8, CBDCA

For research use only.

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Carboplatin (NSC 241240) Chemical Structure

CAS No. 41575-94-4

Selleck's Carboplatin (NSC 241240) has been cited by 82 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[6]
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  M1L0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCyMVI26oDLzszN M{P3RlczKGh? M{PmW4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{GwOUc,OjZzM{exNFU9N2F-
Tca8113/CBP  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4eyOlIuOjYkgJpOwG0> MVi3NkBp MYDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{GwOUc,OjZzM{exNFU9N2F-
Tca8113/PYM  NWj6TYNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDYOGs{Oi1{NfMAje69VQ>? MUW3NkBp M{XGeIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{GwOUc,OjZzM{exNFU9N2F-
SKOV3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\KWJE3OCCvZz;tcC=> M3rjflEuPSCm NWO5bVR2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= M1n4UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NFQ{Lz5{NkGzO|A1OzxxYU6=
SKOV3 NInQOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmwMVQh|rypL33s NVPRWIVwOjRxNEivO|IhcA>? M1X6TIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NIDSTlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOVI4Oyd-Mk[xNlUzPzN:L3G+
SKOV3 NV3DW3hxSXCxcITvd4l{KEG|c3H5 NFHPepAzKM7:Zz;tcC=> NYfmT2hiPDhiaB?= Mnr1bY5lfWOnczDhdI9xfG:|aYO= M3XTNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUK1Nlc{Lz5{NkGyOVI4OzxxYU6=
OSA NVXLW5hlS2yxbn;n[Y5q[yCDc4PhfS=> NYfJfnFOOi53L{Wg{txO NX7aU3d5emW|dXz0d{BqdiCub4fldkBkd2yxbomg[o9zdWG2aX;uJIF{KGOxbYDhdoVlKHSxIHXpeIhmeiCETVmxJJNqWk6DIITy[YF1dWWwdB?= M1T6d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUGwOlIxLz5{NkGxNFYzODxxYU6=
A549 M1zDV2Z2[3Srb36gRZN{[Xl? M2TYU|AwOjVxNUCg{txO M3LRdFI1KGh? MWnkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975 MlS3SpVkfGmxbjDBd5NigQ>? NGjQVYwxNzJ3L{WwJO69VQ>? MWKyOEBp MWHkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi NH\XOJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO|MyPyd-MkW5NVc{OTd:L3G+
A549 NWnONYZ5TnWldHnvckBCe3OjeR?= M4jiVlAwOjVxNUCg{txO NUe1cY42OjRiaB?= NUK1UIF3fXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975 NYf1N3l5TnWldHnvckBCe3OjeR?= NIXlSGoxNzJ3L{WwJO69VQ>? NXOxTpJiOjRiaB?= M2rBSpVxemWpdXzheIV{KG2rUj2yNVgh\XiycnXzd4lwdg>? NFj2b4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO|MyPyd-MkW5NVc{OTd:L3G+
A549 M17Bcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PjNlI2KM7:TR?= Mn60NlQhcA>? NVP6dW06cW6qaXLpeJMh[2WubDDndo94fGh? NFq2UnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO|MyPyd-MkW5NVc{OTd:L3G+
H1975 NFvIfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPweWg6OjVizszN MmHDNlQhcA>? MkPEbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NXfnfJl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVc{OTdpPkK1PVE4OzF5PD;hQi=>
MDA-MB-231 Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUmwMVIzOCEQvHevcYw> M2\aZlczKGh? NF3uUmtKSzVywrC9JFg3KM7:TR?= NWPESIV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N|c3QTFpPkK1PFM4PjlzPD;hQi=>
T47D NU\p[3dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H1XlAuOjJyIN88[{9udA>? NEm5dnE4OiCq M1vybWlEPTEEoE2gOFgvQSEQvF2= NWPuUZpiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N|c3QTFpPkK1PFM4PjlzPD;hQi=>
LCTCC NXn2end{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3iVZBNUUN3ME2zMljjiIoEtV2= MoX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{OxOlcoRjJ3N{ezNVY4RC:jPh?=
MCTCC M{\j[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rvbmlEPTB;Mj645qCKyrWP NX\sWHl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3O|MyPjdpPkK1O|c{OTZ5PD;hQi=>
MegTCC NX7WRpk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXqfoZVUUN3ME20MlHjiIoEtV2= NF7IXow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N|E3Pyd-MkW3O|MyPjd:L3G+
MonoTCC NIPEN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH5TWM2OD13LkdihKnDvU1? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MCF7 M{DUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCyNEDPxE1? MXm3NkBp NEjYTVFqdmS3Y3XzJINmdGxiZHXheIghd2ZiSGCx{tIu\GWybHX0[YQhVUOINzDj[Yxtew>? Mm\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkmwNlUoRjJ3N{[5NFI2RC:jPh?=
A-549  MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqwMlUh|ryP MX6yOEBp NITHZo5FVVORwrC= NGX2RodqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 NYixc3ZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVU3QTBpPkK1O|U2PjlyPD;hQi=>
A-549  NGW4cVBCeG:ydH;zbZMhSXO|YYm= MlO4NE42KM7:TR?= MVS0PEBp NXTrSnBrTE2VT9Mg Mnj0d4hwf3NiZXHycJkh[XCxcITvd4l{KG[nYYT1doV{KGmwY3z1[Ilv\yCkbHXiZolv\yCjbnSgZ4hzd22jdHnuJINwdmSnboPheIlwdg>? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NU[5NEc,OjV5NUW2PVA9N2F-
A-549  MX;GeYN1cW:wIFHzd4F6 NWD2SYlIOC53IN88US=> MoXPOFghcA>? MnjzSG1UV8Li NWC0[pBte2ixd4OgZYJmenKjboSgcYlkem:2dXL1cIUh\Gm|coXweIlwdg>? MlO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUW2PVAoRjJ3N{W1OlkxRC:jPh?=
A-549  NYfSZ2ZmTnWldHnvckBCe3OjeR?= NVu3XYlkOC53IN88US=> NYfGeZAzPDhiaB?= NGKyTYtFVVORwrC= NVjJbXFicW6qaXLpeJMhd2ZiY3XscEBucWe{YYTpc47DqA>? M{\KPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W1OlkxLz5{NUe1OVY6ODxxYU6=
RMG-1 M1i5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJ6LkigxtEhOy54IH3nM2w> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{NkmxN{c,OjV5Mk[5NVM9N2F-
FN-RMG-1 NFPmNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\seoc3UUN3ME20NE42KMLzIESuNkBu\y:OCjFOwG0> NFzHRno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyOlkyOyd-MkW3NlY6OTN:L3G+
RMG-1-hFUT M1G2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\ufXJ6UUN3ME21PE4yKMLzIEKuOEBu\y:O M4X0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K2PVE{Lz5{NUeyOlkyOzxxYU6=
FN-RMG-1-hFUT MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFzOD64JOKyKDF|LkigcYcwVA>? MlrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
CHP-134  Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPYeWoyKM7:TR?= MmX2SG1UV8Li M4TON4lvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? MoTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUi0OlMoRjJ3NkW4OFY{RC:jPh?=
IMR-32 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;OZVEh|ryP NWrGWVNRTE2VT9Mg Ml\nbY5pcWKrdIOgd4lodmmoaXPhcpQh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy NHv5Sm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PFQ3Oyd-MkW2OVg1PjN:L3G+
CHP-134  Mn2ySpVkfGmxbjDBd5NigQ>? NIrycpYyOCEQvF5CpC=> NUj1WYVVTE2VT9Mg NIjFdJlqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? NH7oe4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PFQ3Oyd-MkW2OVg1PjN:L3G+
IMR-32 M2jqXWZ2[3Srb36gRZN{[Xl? NXrVfItlOTBizszNxsA> Ml;iSG1UV8Li NE\sUm1qdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? NFHtWWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PFQ3Oyd-MkW2OVg1PjN:L3G+
A549 NHjrPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7FO5QxNjJvNECwNEDPxE1? NFHubJc4OiCq M3fLS2lEPTB;MUK2JOKyKDVwMDFOwG0> NWSyR3l5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlUzPDNpPkK1OlI2OjR|PD;hQi=>
A549/CDDP NEnnb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCwMlIuPDByMDFOwG0> MlTDO|IhcA>? NYXTXXA3UUN3ME2yOFDDqMLzwrC0OU44KM7:TR?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NUK0N{c,OjV4MkWyOFM9N2F-
H460  MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uxeVI1KGh? NIDYUHRFVVOR NGDPR|FKSzVyPUeuPUDPxE1? NXrCR|Z7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVk6QTVpPkK1OVk6QTl3PD;hQi=>
H460  MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPqO{46KM7:TR?= NFqyOIozPCCq NXj5bplHTE2VTx?= MoDvd4hwf3NiYTDyZYRqd3OnboPpeIl7cW6pIHXm[oVkfCC2bzDYMZJigXN? M3HIV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUm5PVk2Lz5{NUW5PVk6PTxxYU6=
NRK-52E M4TzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\HVlczyqCqwrC= MofLTWM2OD1zMECgxtEhOTJwOTFOwG0> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4NU[wN{c,OjV3NkW2NFM9N2F-
RGE M3XFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonWO|LDqGkEoB?= MlKxTWM2OD1{MjFCtUA4NjRizszN MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4NU[wN{c,OjV3NkW2NFM9N2F-
NRK-52E NEnSbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnGxO|LDqGkEoB?= NXfLe2J{UUN6ME2xO|khyrFiOT61JO69VQ>? M4TSPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[1OlA{Lz5{NUW2OVYxOzxxYU6=
RGE NXnheXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrFT404OsLiaNMg NEjqbpVKSzhyPU[zJOKyKDdwNDFOwG0> NHzWZpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2OVYxOyd-MkW1OlU3ODN:L3G+
SK-OV-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1z3[VczKGh? NHnyUo9KSzVyPUGwOE45KM7:TR?= M2DoNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
ES-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\vcVczKGh? M4qwWGlEPTB;MUSuOkDPxE1? MlPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkCxN|IoRjJ3NUKwNVMzRC:jPh?=
OVCAR-8 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n6OlczKGh? MUXJR|UxRTl4LkCg{txO NF7LT4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyNFE{Oid-MkW1NlAyOzJ:L3G+
3AO MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnziO|IhcA>? MXnJR|UxRTZ|LkSg{txO NH;M[Ig9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyNFE{Oid-MkW1NlAyOzJ:L3G+
A2780 M1nMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLSO|IhcA>? NH7UT|JKSzVyPUG0OU44KM7:TR?= Ml63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkCxN|IoRjJ3NUKwNVMzRC:jPh?=
SW626 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfQZ|g4OiCq NH;ze3hKSzVyPUm3MlAh|ryP MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
OVCAR-3 NFTjNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe3NkBp MoDwTWM2OD1|Mj62JO69VQ>? Ml3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkCxN|IoRjJ3NUKwNVMzRC:jPh?=
A549 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT0bFZiUUN3ME2xOVEvPTZiwsGgOVMvODZizszN M1vmc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
4T1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zZ[GlEPTB;OESuOlIhyrFiM{CuNFUh|ryPCjFOwG0> MkP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
BALB/3T3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF2LkOwJOKyKDZwNkig{txO MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
B16 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG1TWM2OD14ND6zNEDDuSB4LkixJO69VQ>? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
DU 145 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDNVWw3UUN3ME2zOU4xPCEEsTCxO{42PCEQvF2= M3joZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
FaDu Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD5XlhqUUN3ME20OU4{QSEEsTCxNU42OCEQvF2= MmG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
HCV-29T M1rFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXsTWM2OD12OD61O{DDuSB{Mj60PUDPxE1? NYXSXZMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
HL-60 NV7BWI9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFzLkGwJOKyKDRwNEeg{txO MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
HT-29 M4XIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULxUJFZUUN3ME24PU4yPiEEsTCxPE45PiEQvF2= NUHKcpc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
H146 NH;YUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17jT2lEPTB;NEmuOuKyOTNwMTFOwG0> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H187 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXGTWM2OD1zMj63xtEzNjdizszN MojJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
H128 NH7uWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFyNj60xtE6NjZizszN MkOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
H69 NXHaWHRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXOwcWxOUUN3ME23Ok46yrF{Nz64JO69VQ>? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H209 M{f2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfhc4VKSzVyPUK1PE4yyrF7OT64JO69VQ>? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
DMS153 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W4TGlEPTB;NUeuPOKyQS5{IN88US=> NFfMN|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
H526 NEHiPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rtd2lEPTB;Nz6yxtEyNjdizszN NX3p[4JWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
DMS114 NVjFZYVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq0NHhmUUN3ME24OU45yrFzMj64JO69VQ>? MmrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
DMS53 NHTKVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHDSZRKUUN3ME2xOFYvOsLzM{[uOEDPxE1? MnPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
HeLa MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK1MVgxKM7:TR?= MUXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NInuXpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVM3OCd-MkWxNFk{PjB:L3G+
MCF-7 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS4[oo2NThyIN88US=> M1PSO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NXTsUZhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFk{PjBpPkK1NVA6OzZyPD;hQi=>
MDA-MB-231 NUXS[FlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nje|UuQDBizszN M37KS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NIPvVnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVM3OCd-MkWxNFk{PjB:L3G+
CaOV3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\HO|IhcA>? MWrJR|UxRTh4LkGg{txO MkTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
OVCAR-3 NEexcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPmO|IhcA>? MVvJR|UxRTF5OT61JO69VQ>? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
OVCAR-5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVO3NkBp NHW1R3ZKSzVyPUe1Mlch|ryP MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
SKOV-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUG3NkBp NEGxWZdKSzVyPUWwOEDPxE1? NUnIfYN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlg5PDlpPkK1NFY5QDR7PD;hQi=>
OVCAR-4 M1HHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfRcXY4OiCq MlLKTWM2OD1{OUCuOkDPxE1? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
OVCAR-8 M3TpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPPbIlxPzJiaB?= NEDMVHdKSzVyPU[5NE4zKM7:TR?= NH2wdpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
MA148 NWL0VlEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYiyOEBp MUDJR|UxRTh|LkdihKnDueLCiUGuOEDPxGdxbXy= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
A549 NFq1Z2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7iXYgzPCCq MUXJR|UxRTd5Nj6w5qCKyrIkgJmxMlkh|rypL33s NIW5WHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
MDA-MB-231 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOyOEBp M2nB[GlEPTB;N{S4MlDjiIoEsfMAjVEvOSEQvHevcYw> NHntcWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
NCI-ADR/RES  MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;tfVI1KGh? MULJR|UxRTF5NUOuNQKBkcLz4pEJOE41KM7:Zz;tcC=> M2HleFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MA148 NEnSZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW0PEBp M4S0RmlEPTB;MkiuNgKBkcLz4pEJNU4xKM7:Zz;tcC=> MkPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549 MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr2flU1QCCq MlTXTWM2OD1zMUiuNQKBkcLz4pEJNU4zKM7:Zz;tcC=> NETjXHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
MDA-MB-231 NUnTbHI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LFfVQ5KGh? MXTJR|UxRTF6Mz6w5qCKyrIkgJmxMlIhKM7:Zz;tcC=> MoXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
NCI-ADR/RES  M2Xt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjmfWJHPDhiaB?= NGH3OVlKSzVyPUG5N{4x6oDLwsJihKkyNjlizsznM41t MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
MA148 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWi3NkBp NWfLU3NvUUN3ME2xN{446oDLwsJihKkyNjJizsznM41t NE[xbGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
A549 MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHra[HM4OiCq Mn\oTWM2OD14ND6z5qCKyrIkgJmxMlEh|rypL33s NITmSlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
MDA-MB-231 M1HN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXNOHJ6PzJiaB?= MkfFTWM2OD17OT615qCKyrIkgJmxMlEh|rypL33s M33SXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
NCI-ADR/RES  NGH6PJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[5fYs4OiCq NHHUc|BKSzVyPUO3MlTjiIoEsfMAjVEvPyEQvHevcYw> NVyzclZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
A549 M2nHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTkO|IhcA>? MnKxSG1UVw>? NEmwNpRKSzVyPUG1Nk41ODlizszN NHHjcpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyNVMzOyd-MkS3NlE{OjN:L3G+
NCI-H157 MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7yO|IhcA>? Ml;YSG1UVw>? MYfJR|UxRTh7Lkm3O{DPxE1? MkTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkGzNlMoRjJ2N{KxN|I{RC:jPh?=
PC9 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fUWVczKGh? MV7HR|UxRTdzLkdCtVkvPSEEtV2= NUixeXpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVg5ODlpPkK0OlE5QDB7PD;hQi=>
A549  NIrxZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHXO|IhcA>? M1SzeWdEPTB;MUO2xtE{OS54INM1UeKh NIHsfXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[xPFgxQSd-MkS2NVg5ODl:L3G+
PC9 MV7BdI9xfG:|aYOgRZN{[Xl? M3jqS|ExOCEEtV2= M3T2SFczKGh? M1TxRolv\HWlZYOgZZBweHSxc3nz MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzOEiwPUc,OjR4MUi4NFk9N2F-
A549  NI\MPIpCeG:ydH;zbZMhSXO|YYm= NWLUTGZkOTByINM1US=> MW[3NkBp NGHLdJNqdmS3Y3XzJIFxd3C2b4Ppdy=> MnPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUi4NFkoRjJ2NkG4PFA6RC:jPh?=
A549 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHYNHBPOjRiaB?= NHqySnNKSzFyPUGuOFc3KG6P NVfacIkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N|k3PDN5PD;hQi=>
H1299 NVLtNW5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7D[mQzPCCq MV;JR|ExRTBwNESzJI5O NXHudHZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N|k3PDN5PD;hQi=>
HCC15 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\PNlQhcA>? M1fGfWlEOTB;MD6zOFYhdk1? M1TTOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m2OFM4Lz5{NEO5OlQ{PzxxYU6=
H157 M4m5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fDd|I1KGh? MYTJR|ExRTBwOEGgcm0> M3vQcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m2OFM4Lz5{NEO5OlQ{PzxxYU6=
A2780 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL2TWM2OD1zND6w5qCKyrIkgJmxMlQh|ryP NELWVYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
A2780cisR NEPPeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDpTWM2OD12OD655qCKyrIkgJmzMlkh|ryP M4\HRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=
A2780ZD0473R NVexco8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:zTodKSzVyPU[0MlbjiIoEsfMAjVMvOiEQvF2= NFnYclA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
SKOV-3 NIPpVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Llb2lEPTB;NEOuOQKBkcLz4pEJN{46KM7:TR?= NFyzeok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
Assay
Methods Test Index PMID
Western blot pChK-2 / Chk-2 ; p-p53(S15) / p-p53(S46) / p-p53(S392) / p53 ; p-p38 / p38 / Cleaved PARP / PARP 30049957
Immunofluorescence γH2AX 24348048
Growth inhibition assay Cell viability 24348048
In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.

  • (Only for Reference)
Animal Research:

[1]

  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Dosages: ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
  • Administration: Administered via i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

Water 14 mg/mL warmed
(37.71 mM)
DMSO Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage 2 years 4°C(in the dark) powder
Smiles C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05181462 Not yet recruiting Drug: Carboplatin|Drug: Gemcitabine|Drug: Nadunolimab Triple Negative Breast Cancer Cantargia AB|Spanish Breast Cancer Research Group January 2022 Phase 1|Phase 2
NCT04907968 Recruiting Drug: XMT-1536 (Upifitamab Rilsodotin)|Drug: Carboplatin Platinum-sensitive Ovarian Cancer (UPGRADE-A) Mersana Therapeutics|IQVIA Biotech June 11 2021 Phase 1|Phase 2
NCT04606914 Recruiting Drug: mirvetuximab soravtansine (MIRV; IMGN853) Ovarian Cancer|Fallopian Tube|Primary Peritoneal Cancer University of Alabama at Birmingham May 27 2021 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Can you advise what solvent to use and the concentration for S1215 for in vitro use?

Answer:
DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Tags: buy Carboplatin (NSC 241240) | Carboplatin (NSC 241240) supplier | purchase Carboplatin (NSC 241240) | Carboplatin (NSC 241240) cost | Carboplatin (NSC 241240) manufacturer | order Carboplatin (NSC 241240) | Carboplatin (NSC 241240) distributor